Literature DB >> 22926944

Accuracy and axilla sparing potentials of sentinel lymph node biopsy with methylene blue alone performed before versus after neoadjuvant chemotherapy in breast cancer: a single institution experience.

Guo-Chun Zhang1, Ning Liao, Zi-Bai Guo, Xue-Ke Qian, Chong-Yang Ren, Meng Yao, Xue-Rui Li, Kun Wang, Jian Zu.   

Abstract

INTRODUCTION: The timing of sentinel lymph node biopsy (SLNB) of breast cancer in the neoadjuvant setting is still controversial. We retrospectively analyzed a Chinese patient cohort with neoadjuvant chemotherapy (NAC) to evaluate the accuracy and axilla sparing potentials of different SLNB timings with methylene blue alone for lymphatic mapping.
MATERIALS AND METHODS: Patients with NAC and axillary lymph node dissection (ALND) and either pre- or post-NAC SLNB were eligible. Clinicopathological characteristics, identification rate (IR), false-negative rate (FNR), accuracy, and positive-predictive value were calculated and compared between the pre- and post-NAC SLNB group using appropriate statistical methods. Axilla sparing potentials of different SLNB timings were evaluated and compared.
RESULTS: One hundred and fifteen eligible cases were included, and 58 had pre-NAC SLNB while the other 57 had post-NAC SLNB. Both groups were comparable in clinicopathological characteristics, neoadjuvant treatments and pathologic complete response rate. IR, FNR, and accuracy of SLNB, as pre-NAC versus post-NAC, were 100 versus 98.2 % (P = 0.496), 0 versus 8.0 % (P = 0.181), and 100 versus 96.4 % (P = 0.239), respectively. Post-NAC SLNB had significantly higher positive-predictive value for ALNs than pre-NAC SLNB (70.0 vs. 36.4 %, P = 0.014), suggesting as high as 63.6 % of ALND performed in the pre-NAC group could have been avoided while only 30 % of ALND in the post-NAC group were theoretically unnecessary.
CONCLUSIONS: Both SLNB timings of breast cancer patients with NAC were feasible and accurate. Although pre-NAC SLNB tends to be better in accuracy, post-NAC SLNB is significantly superior in terms of axilla sparing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22926944     DOI: 10.1007/s12094-012-0885-0

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  26 in total

1.  Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer.

Authors:  Y Xing; M Foy; D D Cox; H M Kuerer; K K Hunt; J N Cormier
Journal:  Br J Surg       Date:  2006-05       Impact factor: 6.939

Review 2.  Controversies in the use of sentinel nodes: microinvasion, post surgery and after preoperative systemic treatment.

Authors:  Paolo Veronesi; Julia Rodriguez-Fernandez; Mattia Intra
Journal:  Breast       Date:  2007-08-13       Impact factor: 4.380

3.  Timing of sentinel lymph node biopsy in patients receiving neoadjuvant chemotherapy for breast cancer.

Authors:  Moshe Zvi Papa; Douglas Zippel; Bella Kaufman; Shani Shimon-Paluch; Ady Yosepovich; Bernice Oberman; Siegal Sadetzki
Journal:  J Surg Oncol       Date:  2008-11-01       Impact factor: 3.454

4.  Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.

Authors:  H M Kuerer; A A Sahin; K K Hunt; L A Newman; T M Breslin; F C Ames; M I Ross; A U Buzdar; G N Hortobagyi; S E Singletary
Journal:  Ann Surg       Date:  1999-07       Impact factor: 12.969

5.  Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

Authors:  Harry D Bear; Stewart Anderson; Roy E Smith; Charles E Geyer; Eleftherios P Mamounas; Bernard Fisher; Ann M Brown; Andre Robidoux; Richard Margolese; Morton S Kahlenberg; Soonmyung Paik; Atilla Soran; D Lawrence Wickerham; Norman Wolmark
Journal:  J Clin Oncol       Date:  2006-04-10       Impact factor: 44.544

6.  Axillary staging prior to neoadjuvant chemotherapy for breast cancer: predictors of recurrence.

Authors:  Kandice E Kilbride; M Catherine Lee; Alexis V Nees; Vincent M Cimmino; Kathleen M Diehl; Michael S Sabel; Daniel F Hayes; Anne F Schott; Celina G Kleer; Alfred E Chang; Lisa A Newman
Journal:  Ann Surg Oncol       Date:  2008-09-11       Impact factor: 5.344

7.  Sentinel lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Austrian Sentinel Node Study Group.

Authors:  Christoph Tausch; Peter Konstantiniuk; Franz Kugler; Roland Reitsamer; Sebastian Roka; Sabine Pöstlberger; Anton Haid
Journal:  Ann Surg Oncol       Date:  2008-12       Impact factor: 5.344

Review 8.  Recent advances in sentinel lymph node biopsy for breast cancer.

Authors:  Amit Goyal; Robert E Mansel
Journal:  Curr Opin Oncol       Date:  2008-11       Impact factor: 3.645

9.  Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer: results of Ganglion Sentinelle et Chimiotherapie Neoadjuvante, a French prospective multicentric study.

Authors:  Jean-Marc Classe; Virginie Bordes; Loic Campion; Herve Mignotte; François Dravet; Jean Leveque; Christine Sagan; Pierre François Dupre; Gilles Body; Sylvia Giard
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544

10.  Sentinel lymphadenectomy for the staging of clinical axillary node-negative breast cancer before neoadjuvant chemotherapy.

Authors:  J-P Menard; J-M Extra; J Jacquemier; M Buttarelli; E Lambaudie; M Bannier; I Brenot Rossi; G Houvenaeghel
Journal:  Eur J Surg Oncol       Date:  2009-01-20       Impact factor: 4.424

View more
  6 in total

Review 1.  Main controversies in breast cancer.

Authors:  Stephane Zervoudis; George Iatrakis; Eirini Tomara; Anastasia Bothou; George Papadopoulos; George Tsakiris
Journal:  World J Clin Oncol       Date:  2014-08-10

2.  Outcomes of Sentinel Node Biopsy for Women with Breast Cancer After Neoadjuvant Therapy: Systematic Review and Meta-Analysis of Real-World Data.

Authors:  Shi-Qian Lin; Nguyen-Phong Vo; Yu-Chun Yen; Ka-Wai Tam
Journal:  Ann Surg Oncol       Date:  2022-01-11       Impact factor: 5.344

3.  Axillary lymph node status, adjusted for pathologic complete response in breast and axilla after neoadjuvant chemotherapy, predicts differential disease-free survival in breast cancer.

Authors:  G C Zhang; Y F Zhang; F P Xu; X K Qian; Z B Guo; C Y Ren; M Yao
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

4.  A mini-review on factors and countermeasures associated with false-negative sentinel lymph node biopsies in breast cancer.

Authors:  Chao Han; Li Yang; Wenshu Zuo
Journal:  Chin J Cancer Res       Date:  2016-06       Impact factor: 5.087

5.  Histologic Grade and Decrease in Tumor Dimensions Affect Axillary Lymph Node Status after Neoadjuvant Chemotherapy in Breast Cancer Patients.

Authors:  Tae Hee Kim; Doo Kyoung Kang; Ji Young Kim; Sehwan Han; Yongsik Jung
Journal:  J Breast Cancer       Date:  2015-12-23       Impact factor: 3.588

6.  Sentinel Node Biopsy after Neoadjuvant Chemotherapy for Breast Cancer: Preliminary Experience with Clinically Node Negative Patients after Systemic Treatment.

Authors:  Alejandro Martin Sanchez; Daniela Terribile; Antonio Franco; Annamaria Martullo; Armando Orlandi; Stefano Magno; Alba Di Leone; Francesca Moschella; Maria Natale; Sabatino D'Archi; Lorenzo Scardina; Elena J Mason; Flavia De Lauretis; Fabio Marazzi; Riccardo Masetti; Gianluca Franceschini
Journal:  J Pers Med       Date:  2021-03-02
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.